Generex Announces Investor Conference Call

Management to Provide Update on Company Initiatives & Strategic Plans

MIRAMAR, Fla.--()--Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it will hold an investor conference call at 10 a.m. Eastern time on Wednesday, February 22, 2017. Dial-in instructions will be issued prior to the date of the call.

The purpose of the conference call will be to provide investors with an update on the Company’s initiatives and strategic plans, including its controlling interest in Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com), the planned acquisition of a controlling interest in Emmaus Life Sciences, Inc. (www.emmauslifescences.com), the Company’s buccal drug delivery platform technologies, and Antigen Express, Inc. (www.antigenexpress.com), the Company’s wholly-owned immune-therapeutics subsidiary.

The call will also afford an opportunity to introduce the Company’s new management team and Board of Directors.

Joseph Moscato, the Generex President & Chief Executive Officer, stated: “I will look forward to the opportunity to introduce my fellow stockholders to our new management team and to discuss with you our vision for the future of Generex.”

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contacts

Generex Biotechnology Corporation
Joseph Moscato, 646-599-6222
or
Todd Falls, 800-391-6755 Extension 222

Contacts

Generex Biotechnology Corporation
Joseph Moscato, 646-599-6222
or
Todd Falls, 800-391-6755 Extension 222